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Natural Killer (NK) cells are endowed with cell-structure-sensing receptors providing inhibitory protection from self-destruction
(inhibitory NK receptors, iNKRs, including killer inhibitory receptors and other molecules) and rapid triggering potential leading
to functional cell activation by Toll-like receptors (TLRs), cytokine receptors, and activating NK cell receptors including natural
cytotoxicity receptors (NCRs, i.e., NKp46, NKp46, and NKp44). NCR and NKG2D recognize ligands on infected cells which may
be endogenous or may directly bind to some structures derived from invading pathogens. In this paper, we address the known
direct or indirect interactions between activating receptors and pathogens and their expression during chronic HIV and HCV
infections.
1.Introduction
Natural Killer (NK) cells represent a highly specialized lym-
phoid population initially identiﬁed by a potent cytolytic
activity against tumor or virus infected cells. Diﬀerent from
T or B lymphocytes, they do not express clonally distributed
receptors for antigen [1, 2], while their function is ﬁnely
regulated by a balance of inhibitory and activating receptors.
NK cell inhibitory receptors, recognizing mostly HLA class I
molecules on “self” cells (notable exceptions to this concept
are represented, among others, by Siglec7 and IRP60 recog-
nizing non-HLA-related structures), turn NK cells “oﬀ”a n d
represent the major failsafe device to prevent NK-mediated
attack of normal HLA class I+ autologous cells. On the other
hand, the “on”signal is deliveredwhen NKcells interact with
target cells that lack MHC class I molecules and at the same
time are triggered through activating molecules expressed by
these cells (Figure 1). Activating stimuli may be delivered to
NK cells through triggering via Toll-like receptors (TLRs)
including TLR2, TLR3, TLR7/8, TLR9, interleukin receptors
(IL-2, IL-12, IL-15, IL-18), and combinations thereof (e.g.,
IL-2+IL-15,IL-2+IL12,IL-12+IL-18),oractivatory recep-
tors representing an array of diﬀerent molecules expressed
on their surface including natural cytotoxicity receptors
( N C R s ) ,N K G 2 D ,N K G 2 C( al e c t i n - t y p et r i g g e r i n gr e c e p t o r
whichdimerizeswithCD94),2B4(CD244),NKp80,DNAM-
1, NTB-A, and the receptor for IgFc (CD16) [3].
The receptors responsible for NK cell activation in the
process ofnatural cytotoxicityare collectivelytermed natural
cytoxicity receptors (NCRs): NKp46 [4, 5], NKp44 [6, 7],
and NKp30 [8]. Their expression is mostly restricted to NK
cells, and particularly in the case of NKp46, they represent
the most accurate surface markers for human NK cell iden-
tiﬁcation. Exceptions for NK cell identiﬁcation have been
documented. NKp44 may be detected on the surface of a
minority of peripheral plasmacytoid dendritic cells [9]b u t
onarelevantfractionoftissue-residentpDC[10]andNKp30
may be expressed by umbilical cord T-lymphocytes upon
activation [11]. While NKp30 and NKp46 enable a precise
identiﬁcationofNKcells,regardless ofwhetherthesecellsare
resting or activated, NKp44 is selectively expressed only by
activatedNKcells[6,7,12]andshouldbediﬀerentiatedfrom2 Journal of Biomedicine and Biotechnology
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Figure 1: Diagram resuming the balance of activating and inhibi-
tory NK cell receptor:ligand relationships.
NKp44 which is constitutively expressed on pDCs in tissues
[10].
NCRs play a major role in NK-mediated killing of most
tumor cell lines, as revealed by monoclonal antibody-med-
iated receptor-masking experiments [3, 12]. Moreover, their
surface density on NK cells correlates with the magnitude of
cytolyticactivityagainst NK-susceptibletargetcells[13].The
ligands recognized by NCRs are still incompletely molecu-
larly deﬁned and may have variable expression on diﬀerent
cells [14]. However, as revealed by cytolytic assays, they are
expressed by cells belonging to diﬀerent histotypes [2, 15–
17] and, in some cases, may be associated to neoplastic cells
(e.g., B7-H6) [18] or to RNA viruses including inﬂuenza,
dengue, or West Nile virus [19, 20]. NKG2D is another
major NK-cell-triggering receptor belonging to the NKG2
family (type II membrane proteins characterized by a lectin-
like domain) [21–23]. Contrary to the NCR, NKG2D is not
restricted to NK cells but may be also expressed by cytolytic
Tl y m p h o c y t e s[ 24]. NKG2D is speciﬁc for stress-inducible
polymorphic MHC-class-I-related chain (MIC), MIC-A and
MIC-Bor ULBPproteins [25],whichmay beexpressed upon
cell infection [26] or transformation [3].
Other triggering surface molecules expressed by NK cells
are shared by other leucocyte types and appear to function
primarily as coreceptors. They may function to amplify sign-
aling by true receptors. Two such coreceptors, 2B4 [27]a n d
NTB-A [28], appear to serve a dual and opposite function,
depending of availability of downstream regulating elements
on their signaling pathways.
A triggering surface molecule termed NKp80 has been
identiﬁed by the generation of speciﬁc mAb (MA152 and
LAP171) [29]. NKp80 is expressed by virtually all fresh NK
cells derived from peripheral blood as well as by a minor
T-cell subset characterized by the CD3+CD56+ surface phe-
notype [30] and binds to AICL on target cells [31]. NKp80
has so far no speciﬁc reactivity with pathogen-associated
structures.
Another molecule behaving as triggering coreceptor in
NK cells was described following attempts to identify the
cellular ligands of triggering receptors [32]. DNAM-1 is a
transmembrane protein involved in lymphocyte adhesion
and signaling. In addition to NK cells, it is expressed also
on T cells, monocytes, and a small subset of B lymphocytes.
The role of DNAM-1 in NK-mediated killing varies with the
diﬀerent target cells analyzed thus far, suggesting diﬀerences
in the expression of DNAM-1 ligands. Indeed, carcinomas
and hematopoietic cell lines express PVR and Nectin-2, and
their lysis involves DNAM-1. On the other hand, most EBV-
transformed B cell lines analyzed do not express PVR nor
Nectin-2, and their lysis does not involve DNAM-1 [32].
Thus, PVR and Nectin-2 represent the major (if not only)
ligands of DNAM-1. As in the case of the other triggering
receptors, the NK cell activation via DNAM-1 is controlled
by HLA-class-I-speciﬁc inhibitory receptors. As a conse-
quence, normal cells are usually protected from lysis.
Other triggering receptors including CD27, CRTAM,
CD96, CD100(SEMA4D), PSGL1, and CD319 (SLAMF7)
may be expressed by NK cells and have known ligands [3].
None of them has been so far reported to signiﬁcantly inter-
act with invading pathogens.
2.NCR-PathogenInteractions
NK cells are a central component of innate immune re-
sponse, comprising the ﬁrst line of defense against a variety
of tumors and microbial pathogens, including viruses, bac-
terial, fungal, and other intracellular parasites [33–36]. The
lytic activity of NK cells is controlled by complex interac-
tions of inhibitory and activating receptors with specialized
signalling machinery, and at times, the possibility to directly
detect pathogen-derived molecules, independent of Toll-like
receptors [2, 37, 38].
In addition to possible direct activation of NK cells via
TLR by pathogen-derived molecular structures (PAMP, e.g.,
LPS, RNA, DNA), accumulating evidences over recent years
have linked NCRs on NK cells with direct or indirect rec-
ognition of pathogen-associated structures. Given their
role for sensing intracellular pathogen-infected cells, under
particular conditions, these observations may bear relevant
importance in the outcome of an immune response.
O n es h o u l da l s oc o n s i d e rt h a t ,e v e ni nt h ep r e s e n c eo f
weak inhibitory activity by KIR or other inhibitory receptors
(e.g., KIR3DL2-HLA-C1 homozygosity), defects in NCR
expression could lead to failure in recognizing pathogen-
associated molecules acting as NCR ligands on infected cells,
leading to variable degrees of derangement in NK cell func-
tion (Figure 2). The balance of KIR carriage:HLA class
I expression and NKG2A/CD94:HLA-E or CD85j(LIR1/
ILT2):/HLA class I expression needs also to be considered
in these cases. In other terms, although KIR:HLA carriage
is known to inﬂuence NK cell activation [39], this pathway
alone is not exhaustively representing overall NK cell func-
tion, for example in KIR-negative CD56bright NK cells, in NK
cell precursors (which are KIR-NKG2A+and KIR-NKG2A−,
resp.), or in CD56dull NK cells carrying KIR2DL3 on an
HLA-C1 homozygous background but in addition express
high levels of CD85J (LIR1/ILT2).Journal of Biomedicine and Biotechnology 3
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Figure 2: Diagram representing possible consequences of activating receptor modulation, alone, on the control of acute or chronic infec-
tions.
NCRs have been found to interact with infected cells
through recognition of virus-encoded molecules. Sendai
virus (SV) haemagglutinin-neuraminidase (HN) and Inﬂu-
enza virus (IV) haemagglutinin (HA) both recognize termi-
nal N-acetylneuraminic acid residues (sialic acids) attached
to Gal. IV HA and SV HN, bind to sialic acid residues on
NKp46 and NKp44 [19, 40], enabling NCR-mediated lysis
of IV or SV-infected cells. Subsequent clinical observations
corroborated these ﬁndings and showed that lethal IV
infection in humans may be associated to absence of NKp46
onNKcells [41]. NKp46is also involvedinthe detectionand
lysis of vaccinia-virus-infected cells, together with NKp30
and NKp44 [42] although viral ligands have not been char-
acterized.
NKp44 has been reported to interact directly to cell-free
mycobacteria or other bacteria [43] and to play a role in the
recognition of virus-infected cells. In fact, following the
original description of a putative interaction of NKp46
with inﬂuenza virus haemagglutinin and Sendai Virus hem-
agglutinin-neuraminidase [19], also NKp44 was found to
interact with these proteins [40]. Direct interaction of
NKp44 with virus-infected cells and with virus or virus-like
particles, has been recently shown also with regard to the
envelopeproteinofﬂavivirus(WestNilevirus,dengueVirus)
[20]. This leaves open the question of the potential relation-
ship of HCV (another member of the Flaviviridae family)
and NCR expression with regard to disease course. NKp44
has been involved in disease pathogenesis also with regard to
HIV. HIV-1-infected CD4+ cells are reported to be targeted
by NK cells via a NKp44L that is induced by an HIVgp41
peptide [44]. The presence of antibodies to this peptide
in vivo would prevent NK cell recognition and disposal of
infected cells. In HIV-infected patients, these antibodies are
correlated with CD4+ cell numbers and NKp44L expression
on CD4+ cells [45]. There has been so far no nearer
characterization of this ligand, although it has been recently
shown that the 3S motif of gp41 binds to gC1qR (a receptor
fortheglobulardomainofC1q)onCD4+ Tcellsandinduces
activation of a signalling cascade that leads to NKp44L
expression also on uninfected CD4+ T cells [46]. Thus,
NKp44 may be involved not only in protection from over-
whelming infection by direct interaction with cells infected
by viruses belonging to diﬀerent virus families (Orthomyxo-,
Paramyxo-, Flavi-, and Lentiviridae) but may also play a role
in the pathogenesis of hyperactivation syndromes (as with
inﬂuenza or dengue) or in immune depletion (e.g., HIV-1).
Several aspects remain be further clariﬁed in this area,
as direct NK-pathogen interaction via an activating receptor
that is only expressed upon NK cell activation (NKp44),
entails recognition only after full NK cell activation and not
upon initial events following virus entry.
In line with what has been recently shown for NKp44,
also NKG2D interacts with multiple cellular- or pathogen-
derived ligands that trigger NK cell cytotoxicity. NKG2D4 Journal of Biomedicine and Biotechnology
binds to the polymorphic MHC-class-I-related chain (MIC),
MIC-A and MIC-B [47], and also binds to UL-16-binding
proteins (ULBPs), which are MHC class-I-like molecules
that are expressed by tumor cell lines. ULBPs enhance the
capacity of NK cells to lyse tumors and to produce cytokines
such as IFNγ and TNFα [48, 49] and are upregulated during
heat shock or during infection with CMV [50, 51].
Opposite to NKp44 and NKp46, there is little evidence
for direct interaction of NKG2D with pathogen(s); how-
ever, its ligands may be either induced or downmodulated
upon infection by several pathogens. In the case of rodent
poxviruses such as ectromelia virus (mousepox virus),
NKG2D ligands are upregulated on infected cells [52, 53],
whileitappearsthathumanpoxvirusessuchasvacciniavirus
do not aﬀect NKG2D expression in their host but rather
aﬀect NKp46, NKp44, and NKp30 through IFN-α-mediated
increased expression [42, 54]. NKG2D appears to play a rel-
evant role in killing HIV-1-infected CD4+ cells, as its ligands
are still expressed in infected cells in vitro [26]. However,
HIV Nef is speciﬁcally downmodulating ULBP2 [55], thus,
preventing NKG2D-mediated cytotoxicity. Downregulation
of NKG2D ligands MIC-A and MIC-B is also induced by
the K5 immune evasion gene of KSHV (HHV-8). The same
gene product also determines downregulation of the ligand
of NKp80 (i.e., AICL), thus, simultaneously maiming both
NK- and T-cell responses against HHV-8 at multiple levels
[56]. Human CMVhas developeda similar protective system
against both NKG2D-expressing T cells and NK cells, as its
UL16 protein binds to 3 or the main NHG2D ligands (i.e.,
M I C B ,U L B P 1 ,U L B P 2 ) ,t h u s ,p r e v e n t i n gt h e mf r o mb e i n g
expressed by infected cells, thereby, avoiding cell killing by
NKG2D-expressing NK cells [57]. A less extensive NKG2D-
Ligand targeting (i.e., MICA alone) has been reported also
for HCV via its NS3/4A serine protease [58]. Overall, there
are still conﬂicting views in this area that could need
additional attention to improve our understanding of the
role played by NKG2D and NKG2D-interference during
infection by intracellular pathogens comparing human and
animal models. Since NKG2D is also expressed by a relevant
proportion of CD8+ CTLs, additional aspects need do be
addressed comprehensively to improve our understanding
of the relative role of NK cells and CD8 CTLs in disease
pathogenesis to help advise possible interventions.
There are few if any reports suggesting a direct inter-
action of other triggering coreceptors 2B4 (CD224) or
DNAM-1or theirligands (i.e.,CD48and poliovirusreceptor
(CD155) and Nectin-2 (CD112) with viral products) [32,
59, 60]. One possible exception is represented by NKp80,
as mentioned above, which is targeted by HHV-8 proteins
which induce downmodulation of its ligand in infected cells.
3.NCRInvolvement inthe Pathogenesisof
NK CellDysfunction DuringHIV Infection
The strongest evidence for a role of the immune system in
controlling HIV-1 disease comes from a number of epidemi-
ological studies demonstrating a strong inﬂuence of indi-
vidual HLA class I alleles on determining the rate of HIV-1
disease progression [61]. Several subsets of cells belonging
to the hematopoietic lineage express receptors that bind to
HLA class I molecules, including CD8+ T cells, monocytes,
dendritic cells, and NK cells.
A number of observations strongly suggest that CD8+ T
cells playan important role in the containment ofHIVinfec-
tion. For example, exposed-uninfected seronegative subjects
lack speciﬁc humoral responses to HIV-1 buthave detectable
CD8+CTL responses and mucosal IgA immunity [62–65].
However, HIV-1-speciﬁc CD8+ T-cell immunity alone is
not suﬃcient to explain the large heterogeneity observed
in the clinical manifestation of HIV-1 disease. More recent
advances in the understanding of the immune response
to viral infections support the involvement of additional
components of the innate immune system in the control of
HIV-1 disease and might help to identify the mechanism
underlying protective immunity in HIV-1 infection.
HIV-1 infection is associated with signiﬁcant changes in
NK cell subset distributions and function in the peripheral
circulation which were detected already at the beginning
of the epidemic and were subsequently systematically eval-
uated and reviewed [66–68]. Several reports have shown
a dramatic reduction in the proportion of CD3− CD56+
NK cells [69, 70], and particularly CD56bright CD16+/− [71].
This reduction appears to be partially attributable to the
emergence of a novel subset of NKcells that is rare in healthy
individuals, CD3− CD56− CD16+ NK cells [68, 72]. Earlier
work showed that NKcells inHIV-viremic patientsdisplayed
afunctionally relevantanddramaticreductioninNCRs[67],
which is accompanied by relevant activation, as determined
by HLA-DRand CD69 expression [73]. A consistent fraction
of these cells fall also in the subsequently identiﬁed CD56−
CD16+ CD3− “exausted” NK cell subset [72]. Since this sub-
set becomes prominent in individuals with active viral repli-
cation at the expense of the two other subsets of cells (i.e.,
CD56dim and CD56bright NK cells), it needs to be accounted
fortoevaluatetheoverallnumberofNKcellsinpatientswith
HIV-1 infection. NK cells with defective NCR expression
in HIV patients, among these also CD3− CD56+ CD16+
NK cells, have strongly reduced NK cell eﬀector func-
tions, including killing, cytokine secretion, and antibody-
dependent cellular cytotoxicity (ADCC), and exhibit aber-
rant DC-editing activity [67, 73, 74]. DC-editing by NK cells
may take place whenever DCs and NK cells interact in sec-
ondary lymphoid organs. DCs that do not express function-
ally relevant HLA classI molecule densities are subject to NK
cell killing (e.g., iDCs and incompletely mature DCs). NK
cellsinturninduceDCmaturationthrough IFN-γ andTNF-
α production [75–79]. Since incompletely mature DCs pro-
duce higher levels of IL-10 and lower quantities of IL-12 and
show less eﬃcient antigen presentation [80], the eﬃciency
of NK-DC interactions “crosstalk” including cytokine pro-
ductionandNKp30/DNAM-1expressionmayvariablyshape
subsequentdownstreamT-cellandB-celladaptiveresponses.
In addition to changes in NK subpopulations associated
with HIV infection, there are also marked changes in NK
surface receptor expression that are related to loss of func-
tion. With HIV viremia, there is an overall decrease in sur-
face receptor density of NKp46 and NKp30 found on freshlyJournal of Biomedicine and Biotechnology 5
drawn NK cells and dysfunction in NKp44 de novo expres-
sion upon stimulation in vitro resulting in what has been
termed an NCRdull phenotype [67]. In the CD56dim subset,
the proportion of cells expressing NKp46 and NKp30 and
theircytolyticactivity decreasewithdisease progression[81].
Moreover, a concomitant increase of KIR density is also
observed not only on CD8+ CTL, but also on NK cells,
thus, setting the basis for an increased inhibitory potential
of cytolyticcells [82–84]. The downmodulation of activating
receptors and upregulation of KIRs result in measurable
functional defects in NK-cell-mediated cytotoxicity regard-
less of the NK cell subpopulation.
The overall cause of NK cell dysfunction during HIV
infection is poorly understood. The induction of NKp44L
by HIVgp41 on infected and uninfected CD4+ cells and the
as yet poorly characterized downmodulation of activatory
receptor and coreceptor ligands are likely to be involved [26,
46]. Despite isolated reports on the possibility of infection of
CD4− expressing or activated NK cells [85, 86], peripheral
NK cells are not infected by HIV [72]. This phenomenon
may be rather attributed to cells diﬀerent from NK cells [87]
a n di sc u r r e n t l yn o tr e g a r d e da sam a j o rm e c h a n i s ml e a d i n g
to NK cell dysfunction.
Antiretroviral treatment (ART) does not signiﬁcantly af-
fect NK cell function recovery, as IFNγ production [88],
and NCR expression may be persistently impaired even after
successful ART and virus control in patients with CD4+
cell numbers >500/μL[ 89]. Variable NCR expression during
ART, thus, appears to contribute to clinical disease course
upon treatment interruption. Thus, diﬀerences in innate
immune balance during ART may be associated to diﬀeren-
tial control of HIV. Their understanding could explain clini-
cal diﬀerences in individual patients that are not reﬂected by
CD4+ cell counts alone.
Overall, therefore, although KIR:HLA carriage may sig-
niﬁcantly aﬀect the course of HIV infection [61, 90, 91],
direct or indirect disruption of NCR/NCR-ligand expression
byHIVrepresents asigniﬁcant eventthat needsto beconsid-
eredin parallel when evaluatingNKcellactivating/inhibiting
balance. Disruption of NK-DC interaction and DC editing
by NK cells via NKp30 [76, 78, 79]a n dD N A M - 1[ 77]i s
likely to lead to ineﬃcient selection of DC maturation
with ineﬃcient downstream antigen-speciﬁc T- and B-cell
responses [74, 92].
4.NCRsin NonhumanPrimatesand
HIV/SIV Infection
Studies describing NKp46, NKp30, NKG2D, and NKp80 in
animal models of HIV infection revealed that NCR expres-
sion in SHIV-infected macaques does not reﬂect the down-
modulation observed in HIV-infected humans [93, 94].
Importantly, defective transcription of NKp44 has been ob-
served in macaques and this explains why no surface expres-
sion of this NCR is detected in macaques (Macaca mulatta
and Macaca fascicularis)[ 93–95], thus, raising questions on
the interpretation of some experiments in this animal model
with regard to NK cell regulation.
On the contrary, although NKp44 transcription and in-
duction appears to be diﬀerently regulated in chimpanzees
[95] compared to humans, this primate species has a full set
of NCRs [96]. A relevant diﬀerence with Homo sapiens relies
in NKp30 expression and regulation and may impact on the
relativeresistancetoprogressiveHIVinfectioninthisspecies.
Indeed, in both uninfected and HIV-infected chimpanzees
NKp30 is not- or poorly expressed but is de novo expressed
at levels comparable to human NK cells upon cell activation
[96]. Thus, even during HIV replication, NK:DC crosstalk
via NKp30 is likely to be dampened and may explain the
low level of immune activation even in the presence of
active replication of a virus that in humans thrives on cell
activation.
5.NCRsandNKCellFunctioninHCVInfection
NK cells have been implicated in all stages of HCV infection
in both genetic and functional studies. This role may
be either direct, by targeting hepatocytes, or indirect by
inﬂuencing other key immunocytes such as DCs or T cells.
NK cells comprise 5–20% of peripheral blood mononuclear
cells but make up a substantially greater proportion (30–
50%) of lymphocytes in the liver [97]. Intrahepatic NK cells
in murine models may behave diﬀerently (i.e., hyporespon-
siveness) compared to NK cells in other districts, due to a
presumed “tolerogenic” environment in the liver. They are
less cytotoxic and have an altered cytokine proﬁle producing
lower levelofIFNγ and greaterlevelsofImmunomodulatory
cytokines, such as IL-10, compared to peripheral blood and
splenic NK cells [98].
Human peripheral blood NK cells are involved in the
acute phase of HCV infection, with an increase in CD56bright
NK cells and associated reduction in CD56dim subset
[99]. A decline in the CD56bright population is observed
in patients spontaneously clearing the virus and reaching
levels comparable to healthy control individuals within 1–3
months. This return to baseline is not observed in those that
proceed to chronic HCV infection. In the acute phase of
infection, expressionofNKG2Disincreased with augmented
IFNγ production and cytotoxicity [99]. In addition, peak
NK cell activation and degranulation precedes or coincides
with peak T-cell responses, and a correlation was observed
between NK cell degranulation and the magnitude of
HCV-speciﬁc T-cell responses [100]. Thus, recent evidences
agree with a direct involvement of NK cell responses during
acute HCV infection favoring induction and priming of
downstream T-cell responses leading to virus clearance.
During chronic HCV infection, peripheral blood NK
cell frequency (both absolute number and percentage of
total lymphocytes) is reduced in chronic HCV compared
with healthy individuals [101–104]. NK cell frequency
increases following successful antiviral therapy [105]. A
reduction in peripheral blood NK cell frequency in patients
with chronic HCV as compared to spontaneous resolvers has
also been noted [106, 107]. These observations may be at
least in part explained by a signiﬁcant reduction of IL-15
(a pivotal cytokine for NK cell development, proliferation,6 Journal of Biomedicine and Biotechnology
and function) concentrations/levels which is observed in
HCV patients as compared to healthy controls [103].
Several studies in chronic HCV patients have docu-
mented a relative increase in circulating CD56bright (but not
CD56dim NK cells) compared to healthy individuals and
spontaneous resolvers [102, 106, 108]. Bonorino et al.
demonstrated that the relative proportions of CD56dim and
CD56bright NK cells in the liver are altered in chronic HCV
observing that 80.5% of intrahepatic NK cells were CD56dim
as compared to 94% in peripheral blood, and 19.5% intra-
hepatic NK cells were CD56bright as compared to 6.0% in
peripheral blood [102]. This implies that the decreased
frequency of CD56dim in the periphery is not related to their
sequestration in the liver, although there are no nearer data
on the relative proportion of CD56dim and CD56bright NK
cells in the healthy liver. Changes in NK cell phenotype
may not necessarily reﬂect changes in subset distribution.
CD56bright NK cells are KIR-negative and NKG2A-positive,
and one of the most consistent ﬁndings so far has been an
increase in NKG2A expression in chronic HCV infection
[108–110]. This occurs on both intrahepatic and peripheral
blood NK populations [102]a n da l s oi n v o l v e sC D 5 6 dim NK
cells.
Contrary to HIV infection, there has been so far less
consensus on NCR expression during chronic HCV infec-
tion. Increased proportions and density of NCRs, including
NKG2C, NKp44, NKp30, and NKp46 have been reported
[108, 111, 112]. Initial reports of decreased expression of
NKp46 [113] have not been subsequently conﬁrmed. Sim-
ilarly, there is conﬂicting evidence with respect to NKG2D
expression which has been reported as being upregulated,
downregulated, and also unchanged during chronic HCV
infection[108,109,112].However,theseapparentlyopposite
ﬁndings couldbe reconciledbydiﬀerenttreatment responses
in diﬀerent cohorts [114].
Thus, the interaction of HCV with NCRs on NK cells is
less direct compared to HIV, as direct virus challenge does
not impair NK cell function [115], and may be mediated
by other as yet poorly understood viral factors [116]o rb y
possible immunogenetic traits that would parallel those ob-
served for the other side of the (NK cell) coin (i.e., KIR:HLA
interactions) [117].
6.NCRsduring Mycobacterium tuberculosis
hominis Infection
Diﬀerent sets of observations support the notion that NK
cells may be involved in the control of mycobacterial infec-
tions, with particular emphasis on Mycobacterium tuberculo-
sis hominis (Mth). First, NK cells from healthy donors(HDs)
can directly respond to products via TLR-2 [118]. More-
over, NK cells respond to mycobacterium-infected mDC
[75]. Direct interaction between NCRs and Mth has been
suggested (see above). A direct link between NK cells and
Mth-infected cells has been shown to be mediated by the
interaction of NKp46- and NKG2D-activating receptors on
NKcellswithinfectedmonocytes[119].Evidencesindicating
a relevant role for NK-mediated control of Mth replication
are provided by experiments using cells from HDs showing
their promotion ofintracellular killing ofmycobacteria [120,
121]andbytheirabilitytolysemonocytesinfectedwithMth,
Mycobacterium tuberculosis bovis Bacille Calmette-Guerin or
Mycobacterium avium intracellulare [122]. In addition, the
recent description of reduced mDC and pDC numbers and
function in patients with TB [123] suggests that this, in
turn, may impair NK cell function (e.g., through impaired
production of cytokines promoting NK cell activation such
as IL-12 and IL-15) contributing to reduce lysis of Mth-
infected macrophages which are, in turn, subjected to the
activation of antiapoptotic pathways by Mth [119, 124].
NK cells have been shown to play a fundamental role in
themaintenance ofeﬃcientAg-speciﬁcCD8+ CTLresponses
in healthy humans with latent Mth infection [125]. In line
with these observations, patients with recent onset of
pulmonary TB have low-level expression of both NKp46and
NKp30 [126], suggesting that NK-cell-driven downstream
adaptive responses may also be defective. In addition, pa-
tients successfully recovering from pulmonary TB with
standard treatment (rifampicin, isoniazid, ethambutol, and
pyrazinamide for 2 months followed by 24 months of
rifampicin and isoniazid) do recover IFNγ production by
NK cells but fail to recover NKp30 and NKp46 expression
[126] and in some cases do so even after 3–5 years from
end of treatment (A. De Maria, personal observation).
These observations could be explained by the hypothetical
scenario of immunogenetically determined regulation on
NCR expression that may inﬂuence diﬀerent interindivid-
ual susceptibility to latent Mth reactivation with onset of
disease.
7.ConcludingRemarks
S of a r ,t h er o l eo fN C R si nt h ei n t e r a c t i o no fp a t h o g e n sw i t h
NK cells has been largely considered ancillary to cytokine- or
TLR-mediatedactivationandtoKIR:HLAmodulationofNK
cell function. Over the last 10 years accumulating evidences
point to the possibility of viruses to directly interact with
NCRs to tamper with their expression and to interfere
with NCR ligand expression on target cells, thus, indirectly
reducing NK cell function irrespective of the KIR:HLA
haplotype (Figure 2).
Improving our knowledge of the mechanism(s) and of
the regulation of NCR expression and function and inte-
grating this information with inhibitory receptor expression
and function will improve the prospective management
of patients with potentially lethal or invalidating acute
infectionsincludinginﬂuenza,dengue,orHCVandoptimize
treatment strategies of chronic invalidating persistent infec-
t i o n ss u c ha sH I V ,T B ,a n dH C V .
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